ImageneBio (IMA) Cash & Equivalents (2020 - 2025)

ImageneBio has reported Cash & Equivalents for 6 years, with the latest figure at $94.5 million in Q4 2025.

• Quarterly Cash & Equivalents rose 680.1% year-over-year to $94.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $94.5 million (up 680.1% YoY) and the FY2025 annual result came in at $94.5 million, up 680.1% from the prior year.
• Cash & Equivalents fell to $94.5 million in Q4 2025 per IMA's latest filing, from $103.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $281.0 million in Q1 2021 and troughed at $12.1 million in Q4 2024.
• A 5-year average of $101.7 million and a median of $63.5 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 89.89% in 2024, then surged 680.1% in 2025.
• Over 5 years, Cash & Equivalents stood at $232.2 million in 2021, then slumped by 74.2% to $59.9 million in 2022, then surged by 100.09% to $119.9 million in 2023, then sank by 89.89% to $12.1 million in 2024, then soared by 680.1% to $94.5 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $94.5 million, $103.2 million, and $58.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.